Redeye is encouraged by FluoGuide announcing a non-exclusive collaboration with global medtech company Olympus.
Redeye judges that FluoGuide’s recently released progress update mostly confirms our expectations.
Redeye comments on FluoGuide’s Q1 2025 report while the company’s phase II HNC interim readout draws ever closer (H2 2025e).
Redeye comments on FluoGuide’s Q4 2024 report. The company is approaching the interim readout of its phase II trial in HNC (H2 2025e), which...
Redeye comments on FluoGuide’s Q3 2024 report, following its recent business update on FG001’s planned development in head and neck cancer.
Redeye comments on Fluoguide’s Q2 2024 report, following its recent cSEK60m directed share issue that came at shareholder-friendly terms.
Redeye comments on Fluoguide raising cSEK60m through a directed share issue.
Redeye comments on Fluoguide’s Q1 2024 report, following its recent announcement of a collaboration with Intuitive Surgical in head and neck...
Redeye is encouraged by Fluoguide delivering on its promises by entering a collaboration in head and neck RAS with market leader Intuitive S...
Redeye comments on Fluoguide’s Q4 2023 report, with the company having recently communicated a strategy update.
Redeye updates its estimates following Fluoguide presenting its strategic update.
Redeye provides an initial comment on Fluoguide communicating a strategic update for FG001’s clinical development.
Redeye comments on Fluoguide’s Q3 2023 report, with the company reporting two solid phase II readouts since our last update.
Redeye judges Fluoguide’s phase IIb trial with FG001 in high-grade glioma meeting its primary endpoint aligned with our expectations.
Redeye notes Fluoguide announcing phase IIa top-line data with FG001 in head and neck cancer.
Redeye comments on Fluoguide’s Q2 2023 report as top-line data from the company’s phase IIb trial in high-grade glioma are just around the c...
Redeye is encouraged by Fluoguide carrying out a smaller directed share issue of cSEK15m in gross proceeds.
Redeye comments on Fluoguide posting solid phase IIa NSCLC data, providing the first out of three phase II top-line readouts that the compan...
Redeye comments on Fluoguide’s Q1 2023 report as we close in on multiple high-impact catalysts in 2023e.
Redeye comments on Fluoguide providing an update on its clinical trial progress.
Redeye comments on Fluoguide’s Q4 2022 report as we enter a catalyst-rich 2023e for the company.
Redeye comments on Fluoguide’s Q3 2022 report at a time when the company is approaching multiple critical catalysts in the coming 12 months.
Redeye comments on Fluoguide posting interim data from its phase IIa trial with FG001 in NSCLC (FG001-CT002).
Redeye comments on Fluoguide’s Q2 2022 report, and we judge that the company is laser-focused on delivering catalysts that will bring FG001 ...
Redeye briefly comments on Fluoguide’s Q1 2022 report.
Redeye comments on Fluoguide presenting clinical trial data from its phase I/II trial in aggressive brain cancer.
Redeye is encouraged by Fluoguide communicating excellent safety and promising early signs of efficacy from the completed first part of its ...
Redeye comments on Fluoguide’s Q4 report, following a relatively calm couple of months on the news front.
Redeye briefly comments on Fluoguide’s directed share issue of some SEK 25m in gross proceeds, announced yesterday evening.
FluoGuide has been demonstrating good progress with its clinical and preclinical programs, and FG001 appears to be exceeding expectations, w...
